[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Dips More Than Broader Market: What You Should Know",
    "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $23.6, denoting a -2.03% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=1f68dd389607560f66850babbe54e642c9f43ca8f72cd8cf2865d3d3a1fef241",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758836702,
      "headline": "Pfizer (PFE) Dips More Than Broader Market: What You Should Know",
      "id": 136888369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Pfizer (PFE) stood at $23.6, denoting a -2.03% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=1f68dd389607560f66850babbe54e642c9f43ca8f72cd8cf2865d3d3a1fef241"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Buy The Pharma Giant Following The Metsera Deal",
    "summary": "Pfizer acquires Metsera for up to $7.3B, aiming to enter the high-growth obesity drug market and diversify its portfolio. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=626b460f02c2662caff02dc5db092abb80b0611df93b20cbd62b2e297daf82ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758820154,
      "headline": "Pfizer: Buy The Pharma Giant Following The Metsera Deal",
      "id": 136886781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458692389/image_458692389.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer acquires Metsera for up to $7.3B, aiming to enter the high-growth obesity drug market and diversify its portfolio. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=626b460f02c2662caff02dc5db092abb80b0611df93b20cbd62b2e297daf82ab"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b7175ae2a9f32a2ad4d5804a9720fc3d8c2f7245edcbb6752a7ead09f0ea09d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758818220,
      "headline": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "id": 136923995,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b7175ae2a9f32a2ad4d5804a9720fc3d8c2f7245edcbb6752a7ead09f0ea09d7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase",
    "summary": "Pfizer Inc. acquires Metsera to enter the weight-loss drug market. Click to see PFE's dividend strength, growth prospects, and what this deal means for investors.",
    "url": "https://finnhub.io/api/news?id=50629930124209d2d383423824bcd877aa1f4ac8284cfcdfc8bc8a792ed8154d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758813754,
      "headline": "Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase",
      "id": 136885927,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. acquires Metsera to enter the weight-loss drug market. Click to see PFE's dividend strength, growth prospects, and what this deal means for investors.",
      "url": "https://finnhub.io/api/news?id=50629930124209d2d383423824bcd877aa1f4ac8284cfcdfc8bc8a792ed8154d"
    }
  },
  {
    "ts": null,
    "headline": "AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer",
    "summary": "AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.",
    "url": "https://finnhub.io/api/news?id=7ed014ff868406eed30f0f521ee6364e01ff8eee4f5da7c2dfbd3246ec462bc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758813600,
      "headline": "AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer",
      "id": 136884811,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.",
      "url": "https://finnhub.io/api/news?id=7ed014ff868406eed30f0f521ee6364e01ff8eee4f5da7c2dfbd3246ec462bc4"
    }
  },
  {
    "ts": null,
    "headline": "Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls",
    "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Amazon.com (AMZN) to Overweight from Equal Weight with a price target of $280, up from $245. Following its cloud market and Anthropic contribution analysis, Wells has increased conviction that Amazon Web Services will see revenue acceleration. Morgan Stanley upgraded ServiceNow (NO",
    "url": "https://finnhub.io/api/news?id=ff0fb17c2ccbe1d6f227737069977b285e87c8988cdf2d3d376e17b68b165083",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758807641,
      "headline": "Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls",
      "id": 136882828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded Amazon.com (AMZN) to Overweight from Equal Weight with a price target of $280, up from $245. Following its cloud market and Anthropic contribution analysis, Wells has increased conviction that Amazon Web Services will see revenue acceleration. Morgan Stanley upgraded ServiceNow (NO",
      "url": "https://finnhub.io/api/news?id=ff0fb17c2ccbe1d6f227737069977b285e87c8988cdf2d3d376e17b68b165083"
    }
  },
  {
    "ts": null,
    "headline": "Does This Acquisition Make Pfizer Stock a Great Buy?",
    "summary": "There's an opportunity to get in on the weight-loss drug craze at a reasonable price.",
    "url": "https://finnhub.io/api/news?id=20615c6e480b93d973ee7b781a5bc28d323fc79d4df146af99be6c75639c5e94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758807000,
      "headline": "Does This Acquisition Make Pfizer Stock a Great Buy?",
      "id": 136883168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There's an opportunity to get in on the weight-loss drug craze at a reasonable price.",
      "url": "https://finnhub.io/api/news?id=20615c6e480b93d973ee7b781a5bc28d323fc79d4df146af99be6c75639c5e94"
    }
  },
  {
    "ts": null,
    "headline": "Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce",
    "summary": "While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.",
    "url": "https://finnhub.io/api/news?id=9e302f6e6ad9e589fa1ad7a2ed8a09bd22a59011910931e0e5f5fa5dfc139ede",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758806101,
      "headline": "Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce",
      "id": 136883950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.",
      "url": "https://finnhub.io/api/news?id=9e302f6e6ad9e589fa1ad7a2ed8a09bd22a59011910931e0e5f5fa5dfc139ede"
    }
  },
  {
    "ts": null,
    "headline": "Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?",
    "summary": "VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.",
    "url": "https://finnhub.io/api/news?id=38def090a0c127104af513227d5e068d4161df78f693d6c227bb45b865a9f39b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758806100,
      "headline": "Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?",
      "id": 136882930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.",
      "url": "https://finnhub.io/api/news?id=38def090a0c127104af513227d5e068d4161df78f693d6c227bb45b865a9f39b"
    }
  },
  {
    "ts": null,
    "headline": "Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company’s Next Phase of Growth",
    "summary": "IRVING, Texas, September 25, 2025--Revision Skincare®, a leader in advanced skincare solutions, today announced the appointment of Lisa Paley as CEO.",
    "url": "https://finnhub.io/api/news?id=fb4b830ac6f3f528ea5978036ebd91d3104b398053947f8f82806e04bde65b77",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758803400,
      "headline": "Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company’s Next Phase of Growth",
      "id": 136882978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "IRVING, Texas, September 25, 2025--Revision Skincare®, a leader in advanced skincare solutions, today announced the appointment of Lisa Paley as CEO.",
      "url": "https://finnhub.io/api/news?id=fb4b830ac6f3f528ea5978036ebd91d3104b398053947f8f82806e04bde65b77"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025",
    "summary": "NEW YORK, September 25, 2025--ESMO Curtain Raiser",
    "url": "https://finnhub.io/api/news?id=7f00da62e991527fbd4140f310caeb2d0e5be252c5736719dac72d83002e6182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758797100,
      "headline": "Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025",
      "id": 136883171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, September 25, 2025--ESMO Curtain Raiser",
      "url": "https://finnhub.io/api/news?id=7f00da62e991527fbd4140f310caeb2d0e5be252c5736719dac72d83002e6182"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Buy and Hold Forever",
    "summary": "These blue chip dividend stocks offer both income and growth potential.",
    "url": "https://finnhub.io/api/news?id=92adb6e93c80f3bdace8afb2d07c4139681eaea7e57b99c28ec9a7327cbf34c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758790800,
      "headline": "3 Top Dividend Stocks to Buy and Hold Forever",
      "id": 136883013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These blue chip dividend stocks offer both income and growth potential.",
      "url": "https://finnhub.io/api/news?id=92adb6e93c80f3bdace8afb2d07c4139681eaea7e57b99c28ec9a7327cbf34c7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.",
    "summary": "Investors once speculated that Pfizer might consider acquiring Viking.",
    "url": "https://finnhub.io/api/news?id=8187fb09c720eb0007c590e51e1b37224fdee0f1d3710cfcb8f8717e859fd2e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758787920,
      "headline": "Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.",
      "id": 136882934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors once speculated that Pfizer might consider acquiring Viking.",
      "url": "https://finnhub.io/api/news?id=8187fb09c720eb0007c590e51e1b37224fdee0f1d3710cfcb8f8717e859fd2e2"
    }
  },
  {
    "ts": null,
    "headline": "Can a multibillion-dollar deal put Pfizer in the obesity big leagues?",
    "summary": "After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.",
    "url": "https://finnhub.io/api/news?id=78b04e842307cb30b0d4566de77ac5e4d752edf54bae418ae5c664d9c31b2193",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758787200,
      "headline": "Can a multibillion-dollar deal put Pfizer in the obesity big leagues?",
      "id": 136882935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "After a couple failed attempts on its own, Pfizer is hitting the M&A gas to bring in candidates that could help it become a weight loss heavyweight.",
      "url": "https://finnhub.io/api/news?id=78b04e842307cb30b0d4566de77ac5e4d752edf54bae418ae5c664d9c31b2193"
    }
  }
]